Drug Trial Radar · NCT01820572
A Study in Maintenance Kidney Transplant Recipients Following Conversion to Nulojix® (Belatacept)-Based
Last checked: Nov 20, 2026Latest source record: Jan 5, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
446
Actual
Start
Mar 27, 2013
Primary completion
Oct 24, 2019
Study completion Oct 24, 2019
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Mar 29, 2013
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary purpose is to assess the benefits and risks of changing from Cyclosporine or Tacrolimus to Belatacept between 6-60 months after kidney transplant.
Conditions
- Kidney Transplantation
Interventions
BelataceptDrug
TacrolimusDrug
CyclosporineDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Who Survive With a Functional Graft at 24 MonthsTime frame: at 24 Months
Locations
117 sites in 10 countries. Site status is shown where the registry gives one.
UAB Division of Nephrology
Birmingham, Alabama
Mayo Clinic Hospital
Phoenix, Arizona
Loma Linda University Medical Center (LLUMC) - Children's Hospital - Transplantation Institute
Loma Linda, California
UCLA Kidney Transplant Research Office
Los Angeles, California
Keck Medical Center of USC (PI Address)
Los Angeles, California
Cedars-Sinai Medical Center
Los Angeles, California
Transplant Research Institute (PI Address)
Los Angeles, California
University of California, San Francisco (UCSF)-Kidney Transplant Service
Sacramento, California
California Institute Of Renal Research
San Diego, California
California Pacific Medical Center, Depart of Transplantation (PI Address)
San Francisco, California
UCSF Medical Center
San Francisco, California
University of Colorado Denver (PI Address)
Aurora, Colorado
Denver Nephrologists, PC
Denver, Colorado
Yale Medical Group
New Haven, Connecticut
Florida Hospital Transplant Institute (PI Address)
Orlando, Florida
Central Pharmacy
St. Petersburg, Florida
Tampa General Medicine Group
Tampa, Florida
Emory University
Atlanta, Georgia
Medical College of Georgia at Augusta University
Augusta, Georgia
RUSH University Transplant Program (PI Address)
Chicago, Illinois
University of Wisconsin School of Medicine and Public Health (PI Address)
Chicago, Illinois
University of Iowa Health Care (PI Address)
Iowa City, Iowa
Tulane University Health Sciences Center
New Orleans, Louisiana
Maine Transplant Program
Portland, Maine
Massachusetts General Hospital
Boston, Massachusetts
Henry Ford's Transplant Institute
Detroit, Michigan
St. Clair Nephrology Research
Roseville, Michigan
Mayo Clinic
Rochester, Minnesota
Washington Univ School of Med
St Louis, Missouri
University or Nebraska Medical Center
Omaha, Nebraska
Saint Barnabas Medical Center
Livingston, New Jersey
University of Buffalo
Buffalo, New York
Recanati/Miller Transplantation Institue (PI Address)
New York, New York
Carolinas Medical Center (PI Address)
Charlotte, North Carolina
Duke University Medical Center
Durham, North Carolina
East Carolina Univ Nephrology Clin Res. Lab
Greenville, North Carolina
University Hospitals Cleveland Medical Center
Cleveland, Ohio
The Cleveland Clinic Foundation
Cleveland, Ohio
Central PA Transplant Foundation
Harrisburg, Pennsylvania
Drexel University College of Medicine
Philadelphia, Pennsylvania
Showing 40 of 117 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.